newsfilter
← Latest News
Business Wire·

Acorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJA®

Up to five approvals expected in 2024 Additional filings expected in Chile in late 2023 and in Mexico and Brazil in 2024 Acorda Therapeutics, Inc. (NASDAQ:ACOR) today announced the submission of new regulatory